Targeting the central melanocortin system for the treatment of metabolic disorders

Keyphrases

• Metabolic Disorders 100%
• Central Melanocortin System 100%
• Melanocortin 1 Receptor (MC1R) 66%
• Melanocortin System 66%
• Phototoxicity 33%
• Behavioral Disorders 33%
• Circuitry 33%
• Clinical Data 33%
• Anorexia Nervosa 33%
• Therapeutic Target 33%
• Drug Target 33%
• Obesity 33%
• Pharmacological Agents 33%
• Receptor-based 33%
• FDA-approved Drugs 33%
• Preclinical Data 33%
• Cachexia 33%
• Therapeutic Targeting 33%
• Peptide Drugs 33%
• Setmelanotide 33%
• Melanocortin 33%
• Syndromic Obesity 33%
• Afamelanotide 33%
• Bremelanotide 33%
• Erythropoietic Protoporphyria 33%
• Hypoactive Sexual Desire Disorder 33%

Medicine and Dentistry

• Metabolic Disorder 100%
• Melanocortin 100%
• Melanocortin Receptor 40%
• Receptor 20%
• Anorexia Nervosa 20%
• Drug Delivery System 20%
• Cachexia 20%
• Phototoxicity 20%
• Erythropoietic Protoporphyria 20%
• Excitement 20%
• Setmelanotide 20%
• Bremelanotide 20%
• Afamelanotide 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanocortin 100%
• Melanocortin Receptor 40%
• Drug Delivery System 20%
• Receptor 20%
• Phototoxicity 20%
• Cachexia 20%
• Behavior Disorder 20%
• Anorexia Nervosa 20%
• Setmelanotide 20%
• Afamelanotide 20%
• Erythropoietic Protoporphyria 20%
• Bremelanotide 20%